0000000001164289

AUTHOR

Makoto Ueno

showing 2 related works from this author

Tissue factor and its procoagulant activity on cancer‐associated thromboembolism in pancreatic cancer

2021

Abstract Pancreatic cancer frequently involves cancer‐associated thromboembolism, which is strongly associated with poor prognosis. Tissue factor, a blood coagulation factor largely produced in cancer patients as a component of extracellular vesicles, plays a key role in the incidence of cancer‐associated thromboembolism in patients with pancreatic cancer. However, no prospective studies have been published on the relationship between tissue factor and cancer‐associated thromboembolism or patient clinical characteristics, including recent chemotherapy regimens. Thus, we aimed to address this in a Japanese cohort of 197 patients and 41 healthy volunteers. Plasma tissue factor levels were mea…

OncologyAdultMaleRiskCancer Researchmedicine.medical_specialtyEnzyme-Linked Immunosorbent AssayThromboplastinCohort StudiesTissue factorExtracellular VesiclesJapanClinical ResearchPredictive Value of TestsPancreatic cancerInternal medicineThromboembolismmedicineConfidence IntervalsHumansRisk factorProspective cohort studyAgedAged 80 and overbusiness.industryCancerpancreatic neoplasmGeneral MedicineExtracellular vesicleOriginal ArticlesVenous ThromboembolismMiddle Agedmedicine.diseasetissue factorPancreatic NeoplasmsOncologyrisk factorRelative riskCase-Control StudiesCohortMultivariate AnalysisOriginal ArticleFemaleextracellular vesiclebusinessCancer Science
researchProduct

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: …

2020

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma (HCC) was published in 2018, and covered the diagnosis, management, treatment and follow-up of early, intermediate and advanced disease. At the ESMO Asia Meeting in November 2018 it was decided by both the ESMO and the Taiwan Oncology Society (TOS) to convene a special guidelines meeting immediately after the Taiwan Joint Cancer Conference (TJCC) in May 2019 in Taipei. The aim was to adapt the ESMO 2018 guidelines to take into account both the ethnic and the geographic differences in practice associated with the treat…

0301 basic medicinemedicine.medical_specialtyESMO guidelinesDrug availability03 medical and health sciences0302 clinical medicineAdvanced diseaseAsian countryconsensuMedicineHCCReimbursementESMO guidelinePan-Asianbusiness.industryCancer conferenceRelapsed Hepatocellular CarcinomaHematologyhepatocellular carcinomaClinical Practice030104 developmental biologyOncologyconsensus030220 oncology & carcinogenesisFamily medicinebusiness
researchProduct